Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead candidate, an inhaled antibiotic.
“A transition from the laboratory into the clinic represents a significant accomplishment and validation of our team’s ability to execute,” said CEO Rob Neville. “ATI was a critical partner as we raised funds to support the discovery phase of the company, most notably a $1.9 million investment from State of Texas’ Emerging Technology Fund.”
Savara’s NanoCluster formulations are based on agglomerated nanoparticles formed through a controlled flocculation process. In addition to developing its own products, the company offers formulation service.
Read the ATI press release.
